Tacrolimus Versus Hydrocortisone in Atopic Dermatitis

• Status: Recruiting
• Trial end date: 2022-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Atopic dermatitis (AD) is a very common inflammatory, genetic skin disorder that occurs more frequently in children. Its exact etiology is not known but it is characterized by pruritic skin reactions with elevation in the levels of inflammatory markers. Corticosteroids are the first line and the mainstay therapy in management of atopic dermatitis but have many local and systemic adverse effects. The study aims to evaluate the efficacy and safety of topical tacrolimus ointment in comparison to topical hydrocortisone cream in management of children diagnosed with atopic dermatitis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Collaborator: National Hepatology & Tropical Medicine Research Institute
• Treatments: Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Hydrocortisone hemisuccinate; Tacrolimus

Criteria

Inclusion Criteria:

• Male or female patients

• 2-16 years old

• diagnosed with Atopic Dermatitis according to Hanifin and Rajka criteria

Exclusion Criteria:

• patients with serious skin disorder other than Atopic Dermatitis

• patients taking systemic corticosteroids or anti-inflammatory medications.